logo
Plus   Neg
Share
Email

Alnylam Expects To Exceed 2020 Goals With Four Marketed Products

Alnylam Pharmaceuticals Inc. (ALNY) said it expects to exceed its 2020 goals with four marketed products, 14 organic clinical stage programs, including 6 in late-stage development, across 4 strategic therapeutic areas, by end of 2020.

The company also announced that it has initiated HELIOS-B, a global Phase 3 placebo-controlled mortality and cardiovascular hospitalization trial with investigational vutrisiran in patients with ATTR amyloidosis with cardiomyopathy.

Alnylam also plans to support the Medicines company's continued efforts with respect to the ORION Phase 3 studies of inclisiran, an investigational RNAi therapeutic targeting PCSK9 in development for the treatment of hypercholesterolemia.

Alnylam also plans to support Sanofi's continued efforts in advancing fitusiran, an investigational RNAi therapeutic in development for the treatment of hemophilia.

Alnylam announced the selection of the initial seven programs in the Regeneron collaboration, including ALN-APP - an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for hereditary cerebral amyloid angiopathy (hCAA) and early onset familial Alzheimer's disease (EOFAD) - and ALN-HTT - an investigational RNAi therapeutic for the treatment of Huntington's disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT